Please login to the form below

Not currently logged in
Email:
Password:

sarilumab

This page shows the latest sarilumab news and features for those working in and with pharma, biotech and healthcare.

After some big setbacks, Sanofi talks up its R&D portfolio

After some big setbacks, Sanofi talks up its R&D portfolio

antibody Praluent (alirocumab) for cholesterol-lowering, IL4 inhibitor Dupixent (dupilumab) for eczema and IL-6 blocker arthritis treatment Kevzara (sarilumab) as well as a clutch of late-stage pipeline projects - before

Latest news

More from news
Approximately 8 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    Further down the line should come other Regeneron collaborations - first the IL-6 inhibitor sarilumab for rheumatoid arthritis and then dupilumab, which targets the IL-4 pathway that's responsible for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics